MGAC-007
/ Canopy Immuno-Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 06, 2026
Preclinical Characterization of MGAC-007, a First-in-Class Antigen Drug Conjugate for AChR⁺ Myasthenia Gravis
(ICNMD 2026)
- "Preclinical data strongly support the continued development of MGAC-007, which demonstrates proof-of-concept safety & efficacy as a non-immunosuppressive first-in-class therapy for AChR⁺ MG. Its potential as a targeted immunotherapy will be further evaluated in an upcoming multinational Phase I clinical trial."
Preclinical • CNS Disorders • Immunology • Infectious Disease • Myasthenia Gravis
1 to 1
Of
1
Go to page
1